港股異動 | 阜博集團(3738.HK)漲超4% 首季在中國收入同比增加超1000萬港元
格隆匯5月10日丨阜博集團(3738.HK)現報30.25港元,漲4.31%,暫成交8909萬港元,最新總市值139億港元。阜博集團近日公佈,集團繼續推進在中國的業務發展,已完成多項重大業務合作簽約,截至3月31日止三個月內在中國的收入相對2020年同期增加超過1000萬港元。董事會對於集團業務前景充滿信心。中信建投證券曾發研報指,公司預計2021年保持⾼速增⻓,業績營收超過8000萬美元。該行預測公司2021-2022年營收有望達到8010萬美元、1.31億美元,淨利潤有望達406萬美元、836萬美元,維持“買⼊”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.